New depression pill zelquistinel passes first safety check in humans
NCT ID NCT04981561
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested the safety of a single dose of zelquistinel, an experimental drug for major depressive disorder, in 68 healthy adults. Researchers monitored side effects and how the drug moves through the body. Since it was a Phase 1 study, it focused on safety and dosing, not on treating depression.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
zelquistinel
What this could lead to
If successful, this could lead to a new oral medication for major depressive disorder.
What could go wrong
This is a very early Phase 1 safety study in healthy people, not patients. It does not test if the drug works for depression, and many drugs fail at this stage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MAJOR DEPRESSIVE DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.